Leica Biosystems Launches a 4-Plex Fluorescent Detection Kit to Advance Cancer Research

NEWCASTLE, United Kingdom (March 4, 2026) – Leica Biosystems, a Danaher company and a global leader in anatomic pathology solutions, streamlines multiplex immunofluorescence (IF) for oncology and translational research with the launch of its BOND 4-Plex Fluorescent Detection Kit for research use only (RUO). The new pre-assembled kit empowers researchers to achieve consistent, high-quality results while preserving tissue morphology.

Multiplex-IF enables spatial characterization of the tumor microenvironment, such as assessing coexpression of immune checkpoints (e.g., PD-1/PD-L1) and T-cell markers (e.g., CD3, CD8) within the same tissue section. By allowing the simultaneous detection of multiple biomarkers with high sensitivity and clear spectral separation, multiplex IF provides in-depth insights into tumor biology and immune response.

Traditional workflows often require tedious and extensive reagent preparation, manual steps, and harsh staining conditions that can compromise tissue quality and reproducibility. The Leica Biosystems BOND 4-Plex Fluorescent Detection Kit RUO reduces these barriers with a pre-assembled kit that integrates seamlessly with the Leica Biosystems BOND RX automated stainer.

“Our mission is to empower cancer researchers with innovative tools that provide deeper insights and advance the frontiers of cancer research,” said Karan Arora, Senior Vice President, Advanced Assays, AI, and Pharma Partnerships at Leica Biosystems. “With the 4-plex fluorescent detection kit, we’re removing workflow barriers and enabling scientists to generate reliable, reproducible data, while preserving the integrity of precious tissue samples. This launch highlights our ongoing investment in technologies that drive discovery and translational breakthroughs, providing researchers with advanced tools to expand understanding of the tumor microenvironment.”

Featuring a pre-assembled design, the kit simplifies reagent setup and reduces preparation time, enabling direct loading onto the BOND RX stainer. Standardized protocols minimize variability and human error, supporting consistent results across experiments with reproducible performance. The innovation also helps in preserving both tissue morphology and antigenicity for accurate downstream analysis. This is achieved through the use of a gentle elution buffer that operates at low temperatures, ensuring the tissue’s structural integrity remains intact.

The BOND 4-Plex Fluorescent Detection Kit RUO is now available to research laboratories across the United States, with additional regions anticipated throughout 2026. For more information or to request a demonstration, click here.

Leica Biosystems is a cancer diagnostics company and a global leader in anatomic and digital pathology solutions. The company offers a comprehensive product range for each step in the pathology process, from sample preparation and staining to imaging and reporting. As the only company to own the full workflow from biopsy to diagnosis, Leica Biosystems is uniquely positioned to break down the barriers between each step. The company’s mission of “Advancing Cancer Diagnostics, Improving Lives” is at the heart of its corporate culture. Leica Biosystems is proud to be a Danaher Corporation subsidiary.

Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of the most important health challenges impacting patients around the world. Danaher’s advanced science and technology – and proven ability to innovate – help enable faster, more accurate diagnoses and help reduce the time and cost needed to sustainably discover, develop and deliver life-changing therapies. Focused on scientific excellence, innovation and continuous improvement, our approximately 63,000 associates worldwide help ensure that Danaher is improving quality of life for billions of people today, while setting the foundation for a healthier, more sustainable tomorrow. Explore more at www.danaher.com.

Media Contact:  Matt McCutcheon, Global External Communications Senior Manager, Leica Biosystems matthew.mccutcheon@leicabiosystems.com

Source: Leica Biosystems